NorthStar Medical Technologies LLC, Commercial Domestic Production of the Medical Isotope Molybdenum-99
NNSA has completed the Final Environmental Assessment for the NorthStar Medical Technologies LLC, Commercial Domestic Production of the Medical Isotope Molybdenum-99. Based upon the analysis in the EA, NNSA has determined that its proposed action-to provide financial assistance to Northstar Medical Technologies LLC in a cost-sharing arrangement under a cooperative agreement to accelerate the establishment of commercial production of molybdenum-99 using accelerator technology and without the use of highly enriched uranium-would result in no significant impacts.
